Researchers discovered that laminins, specifically laminin γ1, play a crucial role in mediating cell attachment and penetration for oncolytic viruses like H-1PV. This finding may lead to the development of more efficient clinical trials with reduced costs and approval times.
A recent study published in the Oncogene Journal revealed that targeting HIF-1α significantly inhibited melanoma growth and amplified immune cell infiltration into tumour microenvironment. The discovery provides a valuable new target for making resistant melanomas more vulnerable to available anti-cancer treatments.
Scientists identified conolidine's interaction with ACKR3/CXCR7, a novel opioid receptor, to increase analgesic activity and block pain relief-dampening effects. A synthetic analogue, RTI-5152-12, was developed to enhance pharmacological properties.
Researchers developed a novel immunotherapy approach using CpG adjuvant to boost immune tolerance to the major cat allergen Fel d 1. The treatment reversed allergy hallmarks and reduced inflammation in allergic mice, offering new hope for treating cat allergy.
The Luxembourg Institute of Health (LIH) research team discovered a key regulator, ZFAND3, that drives glioblastoma invasion by activating specific genes. Deactivating or overexpressing ZFAND3 in GBM cells impaired or enhanced their invasive capabilities, respectively.
Two Luxembourg Institute of Health researchers have been recognized with the prestigious 2019 Galien Prize in Pharmacology for their groundbreaking research on atypical chemokine receptors. Their work has significant implications for understanding various physiological and pathological processes, including immune responses and cancer.
The study has achieved encouraging participation rates with 556 participants agreeing to share their data. Preliminary findings indicate that most enrolled individuals experienced mild symptoms, with common comorbidities including smoking, asthma, and obesity.
Researchers used machine learning to analyze mitochondrial interaction networks and identified specific patterns associated with Parkinson's disease. These patterns were correlated with clinical scores and allowed for accurate diagnosis of PD patients.
Researchers developed LIH383, a novel molecule targeting ACKR3, which modulates natural painkilling and antidepressant properties by reducing opioid peptide levels. This discovery offers an alternative therapeutic strategy for chronic pain, stress, anxiety, and depression, as well as cancer treatment.
The article discusses Luxembourg's expertise in digital health and its role in fighting COVID-19. The country has developed innovative digital solutions, including telemedicine, mobile apps, and AI-powered tools, to support healthcare systems and monitor the pandemic. The 'Predi-COVID' study is a prime example of this efforts, using da...
Researchers at Luxembourg Institute of Health discovered a mechanism to control regulatory T cells, which can either trigger autoimmune diseases or boost anti-cancer responses. A specially designed diet with reduced serine and glycine levels suppressed severe autoimmunity in mice.
The CARDIATEAM project aims to determine the unique characteristics of diabetic cardiomyopathy and identify new biomarkers and therapeutic targets. The study will collect data from 1,600 patients with various cardiometabolic disorders over three years.
Researchers found cancer stem cells can change surface markers in response to environmental stressors, making targeted therapies less effective. The study's findings could lead to more optimized treatments by understanding how tumor cells adapt to their microenvironment.
Researchers from the Luxembourg Institute of Health uncover distinct microglial signatures in response to acute inflammation, highlighting potential benefits for resolving inflammation. Their single-cell transcriptomic study provides new resources for understanding brain disorders and developing novel therapeutic strategies.
Research discovered that actin cytoskeleton remodeling in breast cancer cells protects them from immune cell attack by limiting the transfer of cytotoxic proteins. The 'actin response' is associated with increased levels of immune-inhibitory ligands, rendering cancer cells resistant to NK cell-mediated cytotoxicity.
Chronic lymphocytic leukemia (CLL) originates from blood-forming cells and spreads to organs through the bloodstream, suppressing immune response to survive. Researchers propose an immunotherapeutic strategy with two immune checkpoint inhibitors that block disease development in preclinical tests.
Researchers found all frailty scores associated with future mortality, and some linked to cardiovascular disease but none to cancer. Certain scores outperform others for all-cause mortality and cardiovascular health outcomes.
Researchers found that inhibiting autophagy in tumor cells increases the production of CCL5, a cytokine that attracts NK cells. This leads to a significant reduction in tumor size and improved survival rates for melanoma patients.
Scientists at Luxembourg Institute of Health discovered a new molecular mechanism where the human immune system activates T cells to fight off pathogens through the production of glutathione, a substance that stimulates energy metabolism. This discovery offers potential therapeutic strategies for targeting cancer and autoimmune diseases.